Denali Therapeutics Inc. $DNLI Stock Position Raised by Temasek Holdings Private Ltd

Temasek Holdings Private Ltd raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 30.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,012,974 shares of the company’s stock after purchasing an additional 1,657,142 shares during the period. Temasek Holdings Private Ltd owned 4.78% of Denali Therapeutics worth $115,784,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DNLI. Norges Bank acquired a new stake in shares of Denali Therapeutics during the 4th quarter worth approximately $84,525,000. Holocene Advisors LP grew its holdings in shares of Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after purchasing an additional 2,732,540 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Denali Therapeutics by 77.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock worth $63,329,000 after purchasing an additional 1,672,098 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Denali Therapeutics by 8.9% during the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after purchasing an additional 1,064,972 shares in the last quarter. Finally, UBS Group AG grew its holdings in shares of Denali Therapeutics by 111.7% during the 3rd quarter. UBS Group AG now owns 2,012,353 shares of the company’s stock worth $29,219,000 after purchasing an additional 1,061,589 shares in the last quarter. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $22.22 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The company has a market capitalization of $3.53 billion, a PE ratio of -7.72 and a beta of 1.03. Denali Therapeutics Inc. has a one year low of $12.58 and a one year high of $23.77. The business has a 50 day simple moving average of $19.83 and a 200 day simple moving average of $19.47.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the company posted ($0.78) EPS. On average, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.77 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Robert W. Baird lifted their price objective on Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Jefferies Financial Group reissued a “buy” rating and set a $40.00 price objective on shares of Denali Therapeutics in a report on Monday, March 2nd. Leerink Partners cut their target price on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. Morgan Stanley cut their target price on Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, May 22nd. Finally, BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a research report on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $34.25.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.